RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1746172 |
| _version_ | 1818721658582597632 |
|---|---|
| author | Bryan Oronsky Corey A. Carter Scott Caroen Curtis Scribner Arnold Oronsky Tony R. Reid |
| author_facet | Bryan Oronsky Corey A. Carter Scott Caroen Curtis Scribner Arnold Oronsky Tony R. Reid |
| author_sort | Bryan Oronsky |
| collection | DOAJ |
| description | The main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer. |
| first_indexed | 2024-12-17T20:42:14Z |
| format | Article |
| id | doaj.art-7585551884034e63b139be4096e6a690 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-12-17T20:42:14Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-7585551884034e63b139be4096e6a6902022-12-21T21:33:16ZengTaylor & Francis GroupOncoImmunology2162-402X2020-01-019110.1080/2162402X.2020.17461721746172RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"Bryan Oronsky0Corey A. Carter1Scott Caroen2Curtis Scribner3Arnold Oronsky4Tony R. Reid5EpicentRx, IncEpicentRx, IncEpicentRx, IncEpicentRx, IncInterWest PartnersEpicentRx, IncThe main mechanism of action of RRx-001, a pharmaceutically unprecedented sui generis Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.http://dx.doi.org/10.1080/2162402X.2020.1746172immunotherapysmall moleculeerythrophagoimmunotherapeuticmyccd47hemoglobintumor associated macrophage |
| spellingShingle | Bryan Oronsky Corey A. Carter Scott Caroen Curtis Scribner Arnold Oronsky Tony R. Reid RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" OncoImmunology immunotherapy small molecule erythrophagoimmunotherapeutic myc cd47 hemoglobin tumor associated macrophage |
| title | RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" |
| title_full | RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" |
| title_fullStr | RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" |
| title_full_unstemmed | RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" |
| title_short | RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic" |
| title_sort | rrx 001 a first in class small molecule inhibitor of myc and a downregulator of cd47 is an erythrophagoimmunotherapeutic |
| topic | immunotherapy small molecule erythrophagoimmunotherapeutic myc cd47 hemoglobin tumor associated macrophage |
| url | http://dx.doi.org/10.1080/2162402X.2020.1746172 |
| work_keys_str_mv | AT bryanoronsky rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic AT coreyacarter rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic AT scottcaroen rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic AT curtisscribner rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic AT arnoldoronsky rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic AT tonyrreid rrx001afirstinclasssmallmoleculeinhibitorofmycandadownregulatorofcd47isanerythrophagoimmunotherapeutic |